Dinutuximab
WikiDoc Resources for Dinutuximab |
Articles |
---|
Most recent articles on Dinutuximab Most cited articles on Dinutuximab |
Media |
Powerpoint slides on Dinutuximab |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Dinutuximab at Clinical Trials.gov Clinical Trials on Dinutuximab at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Dinutuximab
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Dinutuximab Discussion groups on Dinutuximab Patient Handouts on Dinutuximab Directions to Hospitals Treating Dinutuximab Risk calculators and risk factors for Dinutuximab
|
Healthcare Provider Resources |
Causes & Risk Factors for Dinutuximab |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Dinutuximab (tradename Unituxin) is a drug developed by United Therapeutics for the treatment of high-risk neuroblastoma in pediatric patients. It was approved for use by the United States Food and Drug Administration for use on March 10, 2015.